Novotech awarded CRO Best Practice Award

Sydney-based contract research organisation (CRO) Novotech has been awarded the CRO Best Practice Award for the third time in recent years by Frost & Sullivan.

Established in 1996, Novotech has grown to become Australia’s largest independent CRO. The company provides clinical development services across all clinical trial phases and therapeutic areas, and has been actively involved in hundreds of drug development programs for US and EU registration.

Lynda Shelly, executive director, clinical operations at Novotech, accepting the award from Mark Dougan, Frost & Sullivan Australia's managing director.

Frost & Sullivan’s Sanjeev Kumar said Novotech has “proven its excellence in the Australia and Asia-Pacific market” by delivering services and information that meet or exceed the standards of customers, doctors, patients and regulatory authorities.

“The company has exhibited a unique flexibility in terms of handling small to very large projects,” Kumar stated, referring to Novotech’s technologies for electronic data capture, pharmacovigilance and safety management, and clinical trial management. He added that the company has “created a strong brand perception in the minds of its customers, which has resulted in several long-term partnerships and alliances”.

Novotech CEO Alek Safarian said the company was honoured to be recognised once again with the Frost & Sullivan award. He said the Asia-Pacific is the fastest growing region for clinical research, and demand from Novotech’s USA and EU biotech and pharma sponsors is driving the company’s continued expansion of services in the region